DD238725A5 - Verfahren zur herstellung eine synergistischen mischung von interferonen und tumor-nekrose-faktor - Google Patents
Verfahren zur herstellung eine synergistischen mischung von interferonen und tumor-nekrose-faktor Download PDFInfo
- Publication number
- DD238725A5 DD238725A5 DD85277633A DD27763385A DD238725A5 DD 238725 A5 DD238725 A5 DD 238725A5 DD 85277633 A DD85277633 A DD 85277633A DD 27763385 A DD27763385 A DD 27763385A DD 238725 A5 DD238725 A5 DD 238725A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- ifn
- interferons
- tnf
- interferon
- human
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title claims abstract description 25
- 108010050904 Interferons Proteins 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 8
- 229940047124 interferons Drugs 0.000 title claims description 20
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 206010028980 Neoplasm Diseases 0.000 title abstract description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 24
- 102000003390 tumor necrosis factor Human genes 0.000 claims abstract description 5
- 108010047761 Interferon-alpha Proteins 0.000 claims description 14
- 102000006992 Interferon-alpha Human genes 0.000 claims description 14
- 108010074328 Interferon-gamma Proteins 0.000 claims description 14
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 11
- 102000057041 human TNF Human genes 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 102000008070 Interferon-gamma Human genes 0.000 claims description 6
- 102000002227 Interferon Type I Human genes 0.000 claims description 3
- 108010014726 Interferon Type I Proteins 0.000 claims description 3
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 229940079322 interferon Drugs 0.000 abstract description 7
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 29
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 13
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 102100026720 Interferon beta Human genes 0.000 description 6
- 108090000467 Interferon-beta Proteins 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241001446459 Heia Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001054328 Mus musculus Interferon beta Proteins 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- DLEDLHFNQDHEOJ-UDTOXTEMSA-N mezerein Chemical compound O([C@@H]1[C@H]([C@@]23[C@H]4[C@](C(C(C)=C4)=O)(O)[C@H](O)[C@@]4(CO)O[C@H]4[C@H]3[C@H]3O[C@@](O2)(O[C@]31C(C)=C)C=1C=CC=CC=1)C)C(=O)\C=C\C=C\C1=CC=CC=C1 DLEDLHFNQDHEOJ-UDTOXTEMSA-N 0.000 description 1
- DLEDLHFNQDHEOJ-KVZAMRGJSA-N mezerein Natural products CC1C(OC(=O)C=C/C=C/c2ccccc2)C3(OC4(OC3C5C6OC6(CO)C(O)C7(O)C(C=C(C)C7=O)C15O4)c8ccccc8)C(=C)C DLEDLHFNQDHEOJ-KVZAMRGJSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 108700029353 mouse Ifna Proteins 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843423234 DE3423234A1 (de) | 1984-06-23 | 1984-06-23 | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD238725A5 true DD238725A5 (de) | 1986-09-03 |
Family
ID=6238998
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD85277633A DD238725A5 (de) | 1984-06-23 | 1985-06-21 | Verfahren zur herstellung eine synergistischen mischung von interferonen und tumor-nekrose-faktor |
| DD85295292A DD250053A5 (de) | 1984-06-23 | 1985-06-21 | Verfahren zur herstellung einer synergistischen mischung von interferonen und tumor-nekrose-faktor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD85295292A DD250053A5 (de) | 1984-06-23 | 1985-06-21 | Verfahren zur herstellung einer synergistischen mischung von interferonen und tumor-nekrose-faktor |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4791101A (2) |
| EP (1) | EP0170843B1 (2) |
| JP (1) | JPS6115842A (2) |
| AT (1) | ATE82508T1 (2) |
| AU (2) | AU593212B2 (2) |
| CA (1) | CA1258426A (2) |
| DD (2) | DD238725A5 (2) |
| DE (2) | DE3423234A1 (2) |
| DK (1) | DK282585A (2) |
| GR (1) | GR851492B (2) |
| HU (1) | HU206270B (2) |
| IE (1) | IE59289B1 (2) |
| IL (1) | IL75597A (2) |
| NZ (1) | NZ212513A (2) |
| PH (1) | PH24406A (2) |
| ZA (1) | ZA854682B (2) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0250192A3 (en) * | 1986-06-16 | 1988-02-10 | Genentech, Inc. | Therapeutic compositions |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| EP0216786B1 (en) * | 1984-12-21 | 1992-03-18 | Biogen, Inc. | Purification, production and use of tumor necrosis factors |
| US4828830A (en) * | 1986-01-24 | 1989-05-09 | Genentech, Inc. | Method and composition for prophylaxis and treatment of viral infections |
| NZ219027A (en) * | 1986-01-24 | 1989-09-27 | Genentech Inc | Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin |
| US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
| CA1291706C (en) * | 1986-04-03 | 1991-11-05 | Alfred Rudolph | COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2 |
| US5425940A (en) * | 1986-04-09 | 1995-06-20 | Cetus Oncology Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| CA1290249C (en) * | 1986-04-09 | 1991-10-08 | Cetus Corporation | COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR |
| US4863727A (en) * | 1986-04-09 | 1989-09-05 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| US5362490A (en) * | 1986-07-25 | 1994-11-08 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Human myelomonocyte interferon-gamma, and process for preparation and use thereof |
| IL80005A (en) * | 1986-09-10 | 1992-11-15 | Yeda Res & Dev | Compositions for modulating the effect of tnf and il-1 |
| US4929442A (en) * | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
| US4980160A (en) * | 1986-10-16 | 1990-12-25 | Biogen, Inc. | Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases |
| US4963354A (en) * | 1987-01-21 | 1990-10-16 | Genentech, Inc. | Use of tumor necrosis factor (TNF) as an adjuvant |
| ATE79763T1 (de) * | 1989-04-11 | 1992-09-15 | Boehringer Ingelheim Int | Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen. |
| US6042837A (en) * | 1989-09-20 | 2000-03-28 | Kalland; Terje | Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC) |
| US6126945A (en) * | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
| DE69324671D1 (de) * | 1992-02-10 | 1999-06-02 | Interferon Sciences Inc | Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute |
| US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
| DE69636790T2 (de) * | 1995-07-25 | 2007-10-11 | Toray Industries, Inc. | Interferon-beta gegen knochenerkrankungen |
| US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
| AU785212B2 (en) * | 1999-12-13 | 2006-11-09 | Bioniche Life Sciences Inc. | Therapeutically useful synthetic oligonucleotides |
| US20020091095A1 (en) * | 1999-12-13 | 2002-07-11 | Phillips Nigel C. | Modulation of Fas and FasL expression |
| IT1317835B1 (it) * | 2000-02-15 | 2003-07-15 | San Raffaele Centro Fond | Citochine modificate per uso nella terapia del cancro. |
| US7109303B2 (en) * | 2000-02-15 | 2006-09-19 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
| US7309694B2 (en) * | 2000-02-15 | 2007-12-18 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
| US20020150552A1 (en) * | 2000-09-12 | 2002-10-17 | Lau Allan S. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20020150541A1 (en) * | 2000-09-12 | 2002-10-17 | Gene Trol Biotherapeutics, Inc. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20030129162A1 (en) * | 2000-09-12 | 2003-07-10 | Lau Allan S. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| PT1471974E (pt) * | 2002-02-06 | 2007-10-12 | Ares Trading Sa | Factor de necrose tumural combinado com interferão em doenças desmielinizantes |
| GB0209893D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| US7582313B2 (en) * | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
| US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
| WO2004045376A2 (en) * | 2002-11-15 | 2004-06-03 | The General Hospital Corporation | Screening methods to identify treatments for autoimmune disease |
| DE60333228D1 (de) | 2002-12-02 | 2010-08-12 | Amgen Fremont Inc | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen |
| US20050148512A1 (en) * | 2003-11-10 | 2005-07-07 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
| US20080102054A1 (en) * | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
| DE102012024749A1 (de) | 2012-12-11 | 2014-06-26 | Martin Röcken | Tumorprävention und -therapie durch Induktion einer Tumorseneszenz |
| PL2953634T3 (pl) | 2013-02-07 | 2021-11-22 | The General Hospital Corporation | Sposoby namnażania lub zubożania limfocytów t-regulatorowych |
| CN111879948A (zh) | 2013-10-17 | 2020-11-03 | 综合医院公司 | 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物 |
| EP3294773A1 (en) | 2015-05-15 | 2018-03-21 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| WO2017040312A1 (en) | 2015-08-28 | 2017-03-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| US11266730B2 (en) | 2015-09-29 | 2022-03-08 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for BCG therapy |
| CA3023930C (en) | 2016-05-13 | 2025-09-23 | The General Hospital Corporation | TUMOR-ANTAGONISTIC ANTIBODIES OF THE NECROSIS FACTOR RECEPTOR SUPERFAMILY |
| JP7534215B2 (ja) * | 2018-01-24 | 2024-08-14 | ベイジン パーカンズ オンコロジー カンパニー リミテッド | サイトカイン融合タンパク質 |
| CN113302205B (zh) | 2018-11-15 | 2024-12-06 | 综合医院公司 | 激动性肿瘤坏死因子受体超家族多肽 |
| CN114436088A (zh) * | 2020-11-02 | 2022-05-06 | 奥的斯电梯公司 | 用于电梯轿厢的安全出口组件及电梯系统 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2513124B1 (fr) * | 1981-07-21 | 1989-11-17 | Hayashibara Biochem Lab | Production et applications du facteur de lyse des cellules-cibles |
| JPH0764744B2 (ja) * | 1981-11-21 | 1995-07-12 | 株式会社林原生物化学研究所 | 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤 |
| IL71954A0 (en) * | 1983-06-01 | 1984-09-30 | Genentech Inc | Gamma interferon-lymphotoxin synergism |
| CA1265444A (en) * | 1983-06-27 | 1990-02-06 | Lloyd J. Old | Effect of human tumor necrosis factor and human interferon on human cancer cells and methods |
| DE3421731A1 (de) * | 1984-06-12 | 1985-12-12 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Humaner-tumor-nekrose-faktor |
| DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
-
1984
- 1984-06-23 DE DE19843423234 patent/DE3423234A1/de not_active Ceased
-
1985
- 1985-06-19 GR GR851492A patent/GR851492B/el unknown
- 1985-06-20 EP EP85107618A patent/EP0170843B1/de not_active Expired - Lifetime
- 1985-06-20 US US06/746,793 patent/US4791101A/en not_active Expired - Fee Related
- 1985-06-20 AT AT85107618T patent/ATE82508T1/de not_active IP Right Cessation
- 1985-06-20 PH PH32429A patent/PH24406A/en unknown
- 1985-06-20 DE DE8585107618T patent/DE3586833D1/de not_active Expired - Fee Related
- 1985-06-21 AU AU43931/85A patent/AU593212B2/en not_active Ceased
- 1985-06-21 IE IE154785A patent/IE59289B1/en not_active IP Right Cessation
- 1985-06-21 NZ NZ212513A patent/NZ212513A/xx unknown
- 1985-06-21 HU HU852456A patent/HU206270B/hu unknown
- 1985-06-21 DK DK282585A patent/DK282585A/da not_active Application Discontinuation
- 1985-06-21 DD DD85277633A patent/DD238725A5/de not_active IP Right Cessation
- 1985-06-21 DD DD85295292A patent/DD250053A5/de not_active IP Right Cessation
- 1985-06-21 JP JP60135823A patent/JPS6115842A/ja active Pending
- 1985-06-21 ZA ZA854682A patent/ZA854682B/xx unknown
- 1985-06-21 CA CA000484739A patent/CA1258426A/en not_active Expired
- 1985-06-21 IL IL75597A patent/IL75597A/xx not_active IP Right Cessation
- 1985-06-24 AU AU44167/85A patent/AU4416785A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0250192A3 (en) * | 1986-06-16 | 1988-02-10 | Genentech, Inc. | Therapeutic compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| IL75597A (en) | 1991-11-21 |
| DE3423234A1 (de) | 1986-02-06 |
| HUT37891A (en) | 1986-03-28 |
| IE851547L (en) | 1985-12-23 |
| DD250053A5 (de) | 1987-09-30 |
| EP0170843B1 (de) | 1992-11-19 |
| IL75597A0 (en) | 1985-10-31 |
| DK282585D0 (da) | 1985-06-21 |
| PH24406A (en) | 1990-06-13 |
| GR851492B (2) | 1985-11-25 |
| IE59289B1 (en) | 1994-02-09 |
| US4791101A (en) | 1988-12-13 |
| AU4416785A (en) | 1986-01-02 |
| CA1258426A (en) | 1989-08-15 |
| HU206270B (en) | 1992-10-28 |
| EP0170843A1 (de) | 1986-02-12 |
| ATE82508T1 (de) | 1992-12-15 |
| ZA854682B (en) | 1987-02-25 |
| NZ212513A (en) | 1988-08-30 |
| DK282585A (da) | 1985-12-24 |
| JPS6115842A (ja) | 1986-01-23 |
| AU4393185A (en) | 1986-01-02 |
| AU593212B2 (en) | 1990-02-08 |
| DE3586833D1 (de) | 1992-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD238725A5 (de) | Verfahren zur herstellung eine synergistischen mischung von interferonen und tumor-nekrose-faktor | |
| DE69203443T2 (de) | Verwendung von interleukin-10 in der adoptive immunotherapie von krebs. | |
| DE69033700T2 (de) | Il-11 aus säugetier | |
| DE69023416T2 (de) | Verwendung von il-7 bei arzneimitteln zur steigerung der plättchenherstellung. | |
| DE69019962T2 (de) | Glykoprotein menschlichen ursprungs, physiologisch aktiver faktor, der es enthält und heilmittel daraus. | |
| DE69526206T2 (de) | Verwendung von interleukin-12 fuer die verhinderung von transplantat gegen empfaengerkrankheit | |
| Fransen et al. | Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell lines | |
| DE69520088T2 (de) | Interferon-gamma-induzierendes Polypeptid monoklonal Antikörper, und Zusammensetzung für Interferon-gamma gebunden Krankheiten | |
| DE69020573T2 (de) | Verfahren zur wachstumshemmung von stammzellen. | |
| DE69128476T2 (de) | Adoptive immuntherapie mit interleukin-7 | |
| EP0203580B1 (de) | Gamma-IFN als Wirkstoff zur Hemmung (Verhinderung) von Abbauprozessen im Knochen | |
| Brunda et al. | Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons | |
| DE3686794T2 (de) | Reinigung des natuerlichen kolonie-stimulierenden faktors-1. | |
| DE69125035T2 (de) | Verfahren zur herstellung von interferon-alpha-2 kristallen | |
| DE69533941T2 (de) | Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels | |
| DE2947134A1 (de) | Gereinigte proteine und verfahren zu deren herstellung | |
| DE3520228A1 (de) | Wasserloesliche bioaktive trockenfeststoffzusammensetzung, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate | |
| DE69123361T2 (de) | Verwendung von interleukin-4 zur behandlung der festen tumoren | |
| DE3688671T2 (de) | Menschliches Interferon-beta2A ; Vektoren, die Gene enthalten, die für das genannte Interferon kodieren; Zellinien, die dieses produzieren und Verwendung des genannten Interferons als Pharmazeutikum. | |
| DE69130679T2 (de) | Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation | |
| DE69131202T2 (de) | Die Verwendung von IL-4 und TNF zur Herstellung eines Medikaments zur Behandlung von Krebszellen | |
| EP0438756B1 (de) | Cytostatische und cytotoxische Wirkstoffkombination zur Anwendung in therapeutischen Verfahren | |
| EP0652903A1 (de) | Neues menschliches, rekombinantes interferon gamma | |
| EP0250000B1 (de) | Neue Polypeptide, ihre Herstellung und ihre Verwendung | |
| DE69328437T2 (de) | Interleukine-6 Mutante mit verbesserter biologischer Aktivität im vergleich zu wildtyp IL-6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A5 | Published as prov. exclusive patent | ||
| ENJ | Ceased due to non-payment of renewal fee |